CAR-T cell therapy for relapsed or hard-to-treat blood cancer
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of personalized cell therapy (CAR-T) for adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma that has returned or not responded to standard treatments. The therapy uses your own immune cells to attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have B-cell acute lymphoblastic leukemia (B-ALL) that is refractory or relapsed, or B-cell lymphoma that has failed at least two prior treatments.
- Your cancer cells have a marker called CD19.
- You are generally well enough to participate, with acceptable organ function.
- You are not pregnant or breastfeeding and agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target and destroy leukemia or lymphoma cells that carry the CD19 or CD22 marker. It is for people whose cancer has not responded to other treatments or has returned.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This early-phase trial tests a type of immunotherapy called anti-CD19 CAR-T cells. These are specially engineered immune cells that seek out and destroy cancer cells with a marker called CD19 on their surface. It is for people with B-cell cancers (leukemia or lymphoma) that have not responded to or come back after standard treatments.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
Hear when a new Relapsed or Refractory B Cell Leukemia and Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.